Medicare Compliance & Reimbursement

Why New Part B Drug Model Could Hit Oncology the Hardest

Could prior studies have already proven opposite results? Oncologist organizations have been especially vocal in their dissent concerning the recent proposed rule to makeover the way Medicare Part B pays for prescription drugs provided in physician offices and hospital outpatient departments. The reason, in part, is due to the high prevalence of oncology-related and expensive drugs paid under Part B. [...]
You’ve reached your limit of free articles. Already a subscriber? Log in.
Not a subscriber? Subscribe today to continue reading this article. Plus, you’ll get:
  • Simple explanations of current healthcare regulations and payer programs
  • Real-world reporting scenarios solved by our expert coders
  • Industry news, such as MAC and RAC activities, the OIG Work Plan, and CERT reports
  • Instant access to every article ever published in your eNewsletter
  • 6 annual AAPC-approved CEUs*
  • The latest updates for CPT®, ICD-10-CM, HCPCS Level II, NCCI edits, modifiers, compliance, technology, practice management, and more
*CEUs available with select eNewsletters.